Worldquant Millennium Advisors LLC acquired a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 37,658 shares of the medical research company's stock, valued at approximately $9,815,000.
Several other hedge funds have also recently made changes to their positions in AMGN. Centricity Wealth Management LLC bought a new position in shares of Amgen in the 4th quarter worth about $25,000. Ritter Daniher Financial Advisory LLC DE raised its position in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new position in shares of Amgen in the 4th quarter worth about $34,000. Atala Financial Inc bought a new position in shares of Amgen in the 4th quarter worth about $34,000. Finally, Heck Capital Advisors LLC bought a new position in shares of Amgen in the 4th quarter worth about $36,000. 76.50% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
AMGN has been the subject of a number of research analyst reports. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Royal Bank of Canada decreased their target price on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Guggenheim initiated coverage on Amgen in a research report on Tuesday. They issued a "neutral" rating and a $288.00 target price for the company. Finally, Piper Sandler decreased their target price on Amgen from $329.00 to $328.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $309.22.
Check Out Our Latest Research Report on AMGN
Amgen Stock Performance
Shares of NASDAQ AMGN traded down $0.24 during midday trading on Friday, reaching $271.66. The company's stock had a trading volume of 2,531,997 shares, compared to its average volume of 2,795,937. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a 50 day moving average price of $286.82 and a 200-day moving average price of $286.72. The stock has a market capitalization of $146.07 billion, a P/E ratio of 35.98, a PEG ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the previous year, the business earned $3.96 EPS. The company's revenue was up 9.4% compared to the same quarter last year. As a group, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.
Amgen Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.50%. Amgen's payout ratio is currently 86.86%.
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
